Ymmunobio

Executive Summary

Ymmunobio AG is a Swiss biotechnology company founded in 2012, headquartered in Zurich, focused on developing first-in-class therapeutics for solid tumors. The company's pipeline centers on targeting NPTXR, a tumor-exclusive marker found in over 17 major cancer types, including colorectal, gastric, triple-negative breast cancer (TNBC), and non-small cell lung cancer (NSCLC). Ymmunobio's multi-modal platform encompasses antibody-drug conjugates (ADCs), radiopharmaceuticals, bispecific T-cell engagers (BiTCEs), and CAR-T cell therapies, positioning it to address a broad range of solid tumors with high unmet medical need. Currently in the preclinical stage, the company aims to advance its lead candidates toward clinical development. With a novel target and a versatile platform, Ymmunobio represents an early-stage opportunity in the immuno-oncology space.

Upcoming Catalysts (preview)

• Q4 2026IND Submission for Lead ADC Candidate30% success
• Q3 2026Preclinical Proof-of-Concept Data for NPTXR-Targeted BiTCE50% success
• Q2 2026Partnership or Licensing Deal for Radiopharmaceutical Program20% success